Novel Titanium Sapphire 311nm UV Laser: An Efficacious Alternative to Excimer Lasers for Treatment of Localized Vitiligo

SEOUL, South Korea, March 28, 2019 /PRNewswire/ -- A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, this according to a study recently published in Lasers in Surgery and Medicine [51:239-244 (2019)], the official journal of the American Society for Laser Medicine and Surgery.

Professor Jung Min Bae and his team at the Saint Vincent's Hospital, College of Medicine's Department of Dermatology conducted a randomized controlled trial comparing a 311nm Titanium:Sapphire UV laser (TSL) with a 308nm excimer laser (EL) in the treatment of localized vitiligo.  In this study, 74 paired vitiligo lesions in 21 patients were assigned to either a TSL or EL group.  The lesions were treated twice weekly for 12 weeks and evaluated every 4 weeks, measuring and comparing the extent of re-pigmentation in each group.

In summary, the TSL group showed similar therapeutic effect to the EL group. Particularly, excellent re-pigmentation (76–100%) was observed in 65.0% of facial lesions after 12 weeks of TSL treatment compared to re-pigmentation of 60% in the EL treatment group. These results are encouraging given that laser treatments are widely used to treat localized vitiligo and particularly in facial lesions.

Furthermore, in a separate animal study, 311nm TSL treatment is shown to induce expression of endothelin-1 stem cell factor and WNT7a; cytokines involved in melanocyte differentiation, proliferation, and migration.

"Since we demonstrated that 311nm Ti:Sapphire UV laser and 308nm excimer laser are similarly efficacious and safe as vitiligo treatments in a non-inferiority randomized controlled trial, the 311nm Ti:Sapphire UV laser can serve as an alternative treatment option for localized vitiligo," this according to Professor Jung Min Bae. 

PALLAS is the world's first gain switched, Ti:Sapphire solid state 311nm UV-B laser and is CE Marked as well as FDA cleared for UV phototherapy of psoriasis, vitiligo, atopic dermatitis and leukoderma. The advanced solid-state technology developed and deployed in PALLAS negates the need for excimer gas thereby eliminating consumable costs and laser downtime due to gas replacement servicing.  The lack of excimer gas also increases laser operating safety. PALLAS is a development of and is manufactured by LASEROPTEK Co., Ltd., an innovator and manufacturer of world class laser devices for aesthetic and medical dermatology applications.

To learn more about PALLAS and the entire suite of LASEROPTEK aesthetic and medical dermatology laser systems, please visit www.laseroptek.com.

PALLAS will be on exhibit at the 2019 American Society for Laser Medicine & Surgery (ASLMS) meeting to be held March 27^th thru 31^st in Denver, Colorado, U.S.A (Booth # 101).

About LASEROPTEK Co., Ltd.

LASEROPTEK is a global technology-driven medical device company servicing the aesthetic and medical laser space since the year 2,000. Capitalizing on its in-house R&D capabilities, LASEROPTEK introduces safe, stable and high-quality laser systems linking advanced laser technology, safety and clinical efficacy.

Media Contact:
Ms. Helena Lee, Marketing Director
+82-31-8023-5150
[email protected] 

SOURCE LASEROPEK Co. Ltd.